Form 4: BioMarin Pharmaceutical Inc. Executive Erin Burkhart Reports Stock Sale

Erin Burkhart, GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., reports the sale of 1,344 shares of common stock on February 24, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On February 24, 2025, Erin Burkhart, the GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., sold 1,344 shares of common stock.
• The sale was executed at a price of $68.38 per share.
• The transaction was conducted under a pre-existing 10b5-1 trading plan established on November 26, 2024.
• Following the reported transaction, Burkhart directly owns 13,105 shares of BioMarin common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a stock sale under a pre-arranged trading plan, which doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers or directors, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on any recent non-public information.

Stakeholder Impact

• The stock sale by a company executive could be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the sale relative to the executive's holdings.

Key Dates